Work

Migraine prevention with eptinezumab in real life – a retrospective Swiss cohort study

Year: 2026
Type: article
Abstract: Background Eptinezumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP), has been licensed for the prevention of episodic and chronic migraine. The aim of the present study was to assess the effectiveness and safety of eptinezumab for the prevention of migraine in a real-life clinical setting in Switzerland and to identify predictors for treatment response. Methods This multicenter retrospective cohort study included patients treated with eptinezumab at eleven Swiss headache centers. Over 12 months, patients received up to four infusions of eptinezumab 100 mg or 300 mg administered every three months. Data on effectiveness and tolerability were extracted from patient charts, including prospective daily headache diaries. The primary efficacy endpoint was the proportion of patients achieving a ≥ 50% reduction in monthly migraine days (MMDs) three months after the first infusion. Results A total of 201 patients were included. Mean baseline MMDs were 17.5 and decreased significantly by 7.3 days (95%CI 6.2–8.3, p < 0.001) after the first infusion. This was observed for both the 100 mg and 300 mg doses (100 mg, −7.2, p < 0.001; 300 mg, −7.4, p < 0.001). Three months after eptinezumab administration, 56.0% (95%CI 48.9–62.8) of patients reached the primary endpoint of ≥50% response. 78.5% of patients with a ≥ 50% response maintained the response at month 12. Among the 85 patients (44.0%) who did not achieve a ≥ 50% response after the first infusion, 22 (25.9%) responded after the second infusion, and a further 7 (11.1%) of the remaining non-responders responded after the third or fourth infusion. No response was observed in any of the 11 patients with prior exposure to both CGRP-ligand and CGRP-receptor-targeting therapies. Further analysis showed no clear difference in effectiveness in patients with or without comorbid anxiety or depression. Adverse events after the infusions were reported by 14.9% of patients. The most commonly reported adverse events were rhinosinusitis, constipation, and fatigue. Conclusion Eptinezumab was effective and well tolerated in a real-world Swiss cohort of patients with episodic and chronic migraine, including those with comorbidities and prior preventive medication use. Late response to treatment after the second infusion suggests that some initial non-responders may respond later; this needs confirmation. Clinical trial number Not applicable.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,990
OpenAlex ID: W7233620515
FWCI:
Cites:
Cited by:
Related to: